Immunotherapy has emerged as one of the most promising approaches for ovarian cancer
treatment. The tumor microenvironment (TME) is a key factor to consider when stimulating …

Background Despite major advancements in immunotherapy among a number of solid
tumors, response rates among ovarian cancer patients remain modest. Standard treatment …

Epithelial ovarian cancer (EOC) is the most lethal gynecologic cancer with an imperative
need for new treatments. Immunotherapy has had marked success in some cancer types; …

In the past decade, we have witnessed important gains in the treatment of ovarian cancer;
however, additional advances are required to reduce mortality. With compelling evidence …

Clinical outcomes, such as recurrence-free survival and overall survival, in ovarian cancer
are quite variable, independent of common characteristics such as stage, response to …

The clinical course of ovarian cancer is often marked by periods of relapse and remission
until chemotherapy resistance develops. Patients in remission with minimal disease burdens …

Ovarian cancer is the leading cause of death among gynecological neoplasms, with an
estimated 14,000 deaths in 2019. First-line treatment options center around a taxane and …

Clinical outcomes in ovarian cancer are heterogeneous, independent of common features
such as stage, response to therapy and grade. This disparity in outcomes warrants further …

Clinical outcomes in ovarian cancer are heterogeneous even when considering common
features such as stage, response to therapy, and grade. This disparity in outcomes warrants …

Dramatic increase in the number of immunotherapy clinical trials was seen in the past
decade with promising results in enhancing antitumor immune response and cancer vaccine …